Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

36th Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

30
November 2015

Join us for the 36th Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT) taking place 9-11 December 2015 in Tokyo, Japan.

View Articles

2015 ACCP Annual Meeting

1
September 2015

'- San Francisco, CA, 27-29 September

View Articles

High Court rules that Health Research Authority acted unlawfully over trial transparency

11
August 2015

<p></p>

View Articles

6th AGAH Dermatological Product Development Workshop Highlights

15
July 2015

As a contributing sponsor Richmond Pharmacology recently attended the 6th AGAH Dermatological Product Development Workshop held June 23-24, 2015, in London, UK.

View Articles

Local volunteers play valuable role in developing new medicines in Croydon

21
March 2014

View Articles

Richmond Pharmacology presents latest Thorough QT study at the ASCPT 2014 Annual Meeting

3
March 2014

View Articles

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event